AbbVie has tapped Immunome’s discovery platform in a heavily backended partnership and option agreement in a bid to discover 10 antibody-target pairs from three as-yet-unnamed tumor types.

French-American biotech Amolyt Pharma has raised a €130 million ($138 million) Series C round, planning to use the cash to take its hypoparathyroidism drug into final-stage testing and move another experimental drug into the clinic.

Brian Wiley, chief business officer at Portage Biotech, spoke of striking a balance between in-person and virtual meetings.

Biotech company F2G announced today the FDA has accepted its NDA filing for its antifungal therapy, Olorofim. The FDA has set the Prescription Drug User Fee Act (PDUFA) date for June 17, 2023.

Seattle-based biotech EMulate Therapeutics is working hard on the latter, developing technology that leverages magnetic fields to emulate the information inherent to therapeutic molecules and replicate their therapeutic effects without ever administering the molecules to patients.

Drug developers are designing new psychedelic compounds to treat depression and other mental-health conditions but skip the trip.

While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger.

With pipeline and patent expiration pressures, large pharmaceutical companies will need to strategically acquire or align with biotechnology companies providing potential solutions to core asset life cycle management, as well as accessing proprietary assets to address pipeline gaps.